MIIT said 80% of innovative drug approvals in China in the first three quarters were domestic, with research reporting breakthroughs in oncology, psychiatry, anti-infectives, gout and rare diseases.

2026-10-20

MIIT said 80% of innovative drug approvals in China in the first three quarters were domestic, with research reporting breakthroughs in oncology, psychiatry, anti-infectives, gout and rare diseases.